Multiple Myeloma | Specialty

Dr. Kumar on the Management of Newly Diagnosed Patients With Multiple Myeloma

October 7th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

Dr. Hofmeister on the Treatment of Patients with Newly Diagnosed Myeloma

October 3rd 2017

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

Japan Approves Daratumumab for Relapsed/Refractory Myeloma

October 3rd 2017

The Japanese Ministry of Health, Labor and Welfare has approved the use of daratumumab (Darzalex) for the treatment of adults with relapsed/refractory multiple myeloma.

Experts Discuss Advanced Therapies in Relapsed/Refractory Multiple Myeloma

October 3rd 2017

The advent of new agents and new classes of agents for treating relapsed or refractory multiple myeloma, a notably complex disease state, has stimulated efforts to identify the optimal way to sequence or combine these therapies.

FDA Places Holds on Several Durvalumab Combination Trials

September 8th 2017

The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies.

Dr. Usmani on Potential of Checkpoint Inhibitors in Multiple Myeloma

September 7th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the potential of checkpoint inhibitors as monotherapy and in combination.

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

September 7th 2017

The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma

September 6th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

Dr. Voorhees on Managing TRAEs for Patients With Multiple Myeloma

September 6th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.

Experts Discuss Strategies for Boosting Frontline Responses in Myeloma

September 4th 2017

During the past decade, the treatment of multiple myeloma has significantly changed, enabling more patients to achieve deep and durable responses.

FDA Discloses Data on Halted Pembrolizumab Myeloma Trials

September 1st 2017

The FDA released a statement today providing specific data from 2 phase III trials of pembrolizumab in multiple myeloma that the agency placed clinical holds on in July.

FDA Accepts sNDA for Carfilzomib Label Update in Myeloma

September 1st 2017

The FDA has accepted a supplemental new drug application seeking to add overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.

The Value of MRD Testing in Lymphoid Malignancies

August 29th 2017

MRD Negativity in Multiple Myeloma

August 29th 2017

Reliability of MRD Testing: Sensitivity/Specificity

August 29th 2017

Varying Pertinence: MRD Testing Across Lymphomas

August 29th 2017

How to Properly Utilize MRD Testing

August 29th 2017

An Overview of Minimal Residual Disease Testing

August 29th 2017

Understanding MRD Testing in CLL

August 29th 2017

CLL: MRD Testing Platforms

August 29th 2017